Keywords: K, ICE, Roche, Herceptin, Gastric cancer, Novartis, Glivec, GIST

Roche convinces UK’s NICE to recommend Herceptin for metastatic gastric cancer; Novartis fail in higher dose Glivec

Article | 25 November 2010

Print This

The UK’s drug watchdog, the National Institute for Health and Clinical Excellence (NICE), this week delivery mixed news ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in